iBio Q1 2027 earnings

IBIO · 2026-11-10 16:36 AMC ET · 8-K on SEC

Revenue increased 975% YoY, but the company reported a net loss of $7.55 million, driven by higher R&D expenses.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.08M+975%—Ex. 99.1, income statement
EPS (GAAP)-$0.05+54.5%—Ex. 99.1, income statement
Net income-$7.55M+31.7%—Ex. 99.1, income statement
Adj. EBITDA-$6,746+31.8%—Ex. 99.1, income statement
Adj. EBITDA margin-79.0%+1.2 pp—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $9.41M (+56.3% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge No non-GAAP reconciliation provided.

KPIs

not stated in the 8-K

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue increased to $1.08 million from $100,000 in the prior year.
  • EPS story The EPS improvement (+$0.06) came from a reduction in the net loss driven by higher revenue and interest income.
  • One-off check No one-off items disclosed.

The good

  • Revenue increased 975% YoY.
  • Interest income increased 197% YoY to $787,000.

The bad

  • Net loss increased to $7.55 million from $5.72 million YoY.
  • R&D expenses increased 87.3% YoY to $6.65 million.
  • Operating loss increased to $8.34 million from $5.95 million YoY.

The ugly

  • none

Open questions

  • The release does not provide a reconciliation of GAAP net loss to adjusted EBITDA.
  • The release does not provide a reconciliation of GAAP loss per share to adjusted loss per share.
Full release

iBio (IBIO) earnings release, November 10, 2026

iBio, Inc. (IBIO) · Form 8-K, Item 2.02 · Filed · SEC filing

iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update

Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy

Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600

Plans to participate in upcoming scientific and investor conferences

SAN DIEGO, November 10, 2026 -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the first quarter of fiscal year 2027, ended September 30, 2026, and provided a corporate update on its progress.

“This was a quarter of focus and execution as we advanced our portfolio of long-acting antibody therapeutics designed to address important challenges in obesity care,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “The data presented at EASD strengthen our conviction in IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation as we advance toward an IND-equivalent filing by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027. We also anticipate advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing our preclinical programs that aim to address the entire spectrum of cardiometabolic disease care. Together, this progress brings us closer to our broader goal of helping people living with obesity achieve high-quality weight loss and better long-term health.”

First Fiscal Quarter 2027 & Recent Corporate Updates

Financial Results

About iBio, Inc. iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.

For more information, visit www.ibioinc.com or follow us on LinkedIn.

Financial statements

Income Statement

Three Months Ended — (Unaudited; in thousands, except per share amounts)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025
Revenue1,075100
Operating expenses:
Research and development6,6503,550
General and administrative2,7632,501
Total operating expenses9,4136,051
Operating loss-8,338-5,951
Other income (expense):
Interest income787265
Interest expense-34
Total other income787231
Net loss before income taxes-7,551-5,720
Net loss-7,551-5,720
Comprehensive loss:
Net loss-7,551-5,720
Other comprehensive loss - unrealized loss on debt securities-78-15
Comprehensive loss-7,629-5,735
Loss per common share - basic and diluted-0.05-0.11
Weighted-average common shares outstanding - basic and diluted - see Note 16151,57452,981

Balance Sheet

September 30, — (In thousands, except share and per share amounts)

September 30, – 2026 – (Unaudited)June 30, – 2026
Current assets:
Cash and cash equivalents45,43556,395
Accounts receivable - trade, net of allowance for credit losses of $65 as of September 30, 2026 and June 30, 2026125
Investments in debt securities (adjusted cost $31,342 and $31,689 as of September 30, 2026 and June 30, 2026, respectively - see Note 6)31,21931,644
Promissory note receivable and accrued interest1,1241,104
Prepaid expenses and other current assets3,3363,078
Total Current Assets81,23992,221
Restricted cash228228
Operating lease right-of-use asset, net of accumulated amortization1,5661,667
Fixed assets, net of accumulated depreciation3,0213,086
Intangible assets, net of accumulated amortization2,5701,825
Prepaid expenses - noncurrent73
Security deposits2710
Total Assets88,65199,110
Current liabilities:
Accounts payable4,4094,423
Accrued expenses3,4045,626
Operating lease obligation - current portion561546
Contract liabilities2001,150
Total Current Liabilities8,57411,745
Operating lease obligation - net of current portion1,5071,652
Total Liabilities10,08113,397
Stockholders’ Equity
Common Stock - $0.001 par value; 275,000,000 shares authorized; 64,307,256 and 55,698,561 shares issued and outstanding as of September 30, 2026 and June 30, 2026, respectively (see Note 15)6456
Additional paid-in capital451,448450,970
Accumulated other comprehensive loss-123-45
Accumulated deficit-372,819-365,268
Total Stockholders’ Equity78,57085,713
Total Liabilities and Stockholders’ Equity88,65199,110

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements include, among others, statements regarding IBIO-610’s potential to deliver high-quality weight loss and provide important preclinical validation; iBio advancing toward an IND-equivalent filing for IBIO-610 by the end of 2026, with plans to initiate first-in-human studies in the first half of 2027; advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027 and progressing iBio’s preclinical programs that aim to address the entire spectrum of cardiometabolic disease care; iBio helping people living with obesity achieve high-quality weight loss and better long-term health; the potential that adding IBIO-610 to GLP-1 therapy may improve the quality of weight loss by increasing the proportion of weight lost from fat while preserving muscle; initiating first-in-human trials of IBIO-610 in the first half of 2027; anticipated interim Phase 1 data of the SAD study in the first quarter of 2027; the multiple ascending dose portion of the Phase 1 clinical trial for IBIO-600 anticipated to start in the first quarter of 2027; and iBio’s planned participation in upcoming conferences. These statements reflect iBio’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with meeting anticipated timelines, including an IND-equivalent filing for IBIO-610 by the end of 2026, initiating first-in-human studies in the first half of 2027, advancing IBIO-600 in the multiple ascending dose portion of the Phase 1 trial in the first quarter of 2027, initiating first-in-human trials of IBIO-610 in the first half of 2027 and the multiple ascending dose portion of the Phase 1 clinical trial for IBIO-600 starting in the first quarter of 2027 clinical trial enrollment and execution, the possibility that preclinical findings will not be

​ replicated in humans, product development and regulatory approval, and the other risks described in iBio’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended June 30, 2026, and subsequent filings.

Forward-looking statements speak only as of the date of this release. iBio undertakes no obligation to update them except as required by law.

Investor Contact

Matt Beck astr partners matthew.beck@astrpartners.com

(917) 415-1750

Media Contact

Jason Braco, Ph.D.

Valence Communications jason@valencecomms.com

​ iBio, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited; in thousands, except per share amounts)

​

​

​ iBio, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

​

​

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.